These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28314266)

  • 1. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
    Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A
    Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
    PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.
    Wawruszak A; Luszczki J; Halasa M; Okon E; Landor S; Sahlgren C; Rivero-Muller A; Stepulak A
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
    Ong PS; Wang XQ; Lin HS; Chan SY; Ho PC
    Int J Oncol; 2012 May; 40(5):1705-13. PubMed ID: 22328352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Osthole and Cisplatin Against Rhabdomyosarcoma TE671 Cells Yielded Additive Pharmacologic Interaction by Means of Isobolographic Analysis.
    Jarząb A; Łuszczki J; Guz M; Skalicka-Woźniak K; Hałasa M; Smok-Kalwat J; Polberg K; Stepulak A
    Anticancer Res; 2018 Jan; 38(1):205-210. PubMed ID: 29277774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.
    Gumbarewicz E; Luszczki JJ; Wawruszak A; Dmoszynska-Graniczka M; Grabarska AJ; Jarząb AM; Polberg K; Stepulak A
    Am J Cancer Res; 2016; 6(12):2831-2845. PubMed ID: 28042503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
    Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
    Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
    Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
    Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
    Asgar MA; Senawong G; Sripa B; Senawong T
    Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
    Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
    Heinicke U; Fulda S
    Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
    Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
    Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
    Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.
    Burianova I; Kuzelova K; Mitrovsky O; Spicka I; Stockbauer P; Zackova M
    Neoplasma; 2017; 64(2):228-237. PubMed ID: 28043150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
    Yang B; Yu D; Liu J; Yang K; Wu G; Liu H
    Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
    Kewitz S; Bernig T; Staege MS
    Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
    Gavrilov V; Lavrenkov K; Ariad S; Shany S
    Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.